Development of type 2 diabetes · people at increased risk for developing type 2 diabetes
Acarbose probably leads to lower incidence of T2DM compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · people at increased risk for developing type 2 diabetes
Acarbose showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Cardiovascular mortality · people at increased risk for developing type 2 diabetes
It is very uncertain whether acarbose changes cardiovascular mortality compared with placebo (very low certainty).
1 finding from 1 review
(1) Non‐fatal myocardial infarction (2) Non‐fatal stroke (3) Congestive heart failure · people at increased risk for developing type 2 diabetes
It is very uncertain whether acarbose changes (a)Non‐fatal myocardial infarction (b)Non‐fatal stroke (c)Congestive… compared with placebo (very low certainty).
1 finding from 1 review
Health‐related quality of life · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Socioeconomic effects · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · people at increased risk for developing type 2 diabetes
1 finding from 1 review
Development of type 2 diabetes · people at increased risk for developing type 2 diabetes
It is very uncertain whether acarbose changes incidence of T2DM compared with no intervention (very low certainty).
1 finding from 1 review
IOP increase of ≥ 5 mmHg within 2 hours · people with glaucoma receiving LTP
1 finding from 1 review
Mean change in IOP from pre‐LTP within 2 hours · people with glaucoma receiving LTP
1 finding from 1 review
IOP increase of ≥ 5 mmHg between 2 and 24 hours · people with glaucoma receiving LTP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
IOP increase of ≥ 10 mmHg between 2 and 24 hours · people with glaucoma receiving LTP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean change in IOP from pre‐LTP between 2 and 24 hours · people with glaucoma receiving LTP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events during treatment period · people with glaucoma receiving LTP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
IOP increase of ≥ 5 mmHg within 2 hours · people with glaucoma receiving LTP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
IOP increase of ≥ 10 mmHg within 2 hours · people with glaucoma receiving LTP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean change in IOP from pre‐LTP within 2 hours · people with glaucoma receiving LTP
1 finding from 1 review
IOP increase of ≥ 5 mmHg between 2 and 24 hours · people with glaucoma receiving LTP
1 finding from 1 review
no estimate extracted
Studies not reported
Low
IOP increase of ≥ 10 mmHg between 2 and 24 hours · people with glaucoma receiving LTP
Apraclonidine showed no clear difference in IOP increase of ≥ 10 mmHg between 2 and 24 hours compared with pilocarpine (low certainty).
1 finding from 1 review
IOP increase of ≥ 10 mmHg within 2 hours · people with glaucoma receiving LTP
Medication probably leads to lower IOP increase of ≥ 10 mmHg within 2 hours compared with placebo (moderate certainty).
1 finding from 1 review